Immunization of adults against varicella and herpes zoster;Vaccination des adultes contre la varicelle et le zona

Revue de Medecine Interne

Volumn 28, Issue 3, 2007, Pages 166-172

  Hanslik, T ^a,b   Blanchon, T ^b,c   Alvarez, F P ^b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Chickenpox; Epidemiology; Herpes zoster; Shingles; Vaccination; Varicella

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE; VARICELLA ZOSTER VACCINE;

CHICKENPOX; DRUG SAFETY; FRANCE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFECTION SENSITIVITY; MORBIDITY; MORTALITY; POSTHERPETIC NEURALGIA; SHORT SURVEY; VACCINATION; ADULT; HEALTH CARE POLICY; HEALTH SURVEY; PREVENTIVE HEALTH SERVICE; REVIEW;

ADULT; CHICKENPOX; CHICKENPOX VACCINE; FRANCE; HEALTH POLICY; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; POPULATION SURVEILLANCE;

EID: 33847689783     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.12.004     Document Type: Short Survey

References (44)

1. Conseil supérieur d'hygiène publique de France. Calendrier vaccinal 2006. Bull. Epidemiol. Hebd. 29-30 (2006) 211-216
2. Réseau Sentinelles. Bilans annuels. In: http://rhone.b3e.jussieu.fr/senti/?module=bilans. 2006.
3. Bonmarin I., Ndiaye B., Seringe E., and Levy-Brühl D. Épidémiologie de la varicelle en France. Bull. Epidemiol. Hebd. 8 (2005) 30-32
4. Boëlle P.Y., and Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol. Infect. 129 (2002) 599-606
5. Hanslik T., Boëlle P.-Y., Schwarzinger M., Carrat F., Freedberg K.A., Valleron A.-J., et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 21 (2003) 3614-3622
6. Khoshnood B., Debruyne M., Lançon F., Emery C., Fagnani F., Durand I., et al. Seroprevalence of varicella in the French population. Pediatr. Infect. Dis. J. 25 (2006) 41-44
7. Chidiac C., Bruxelle J., Daures J.P., Hoang-Xuan T., Morel P., Leplège A., et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin. Infect. Dis. 33 (2001) 62-69
8. Czernichow S., Dupuy A., Flahault A., and Chosidow O. Zona : enquête d'incidence chez les médecins généralistes du réseau « Sentinelles ». Ann. Dermatol. Venereol. 128 (2001) 497-501
9. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., and Nikas A.A. The incidence of herpes zoster in a United States administrative database. J. Gen. Intern. Med. 20 (2005) 748-753
10. Thomas S.L., and Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect. Dis. 4 (2004) 26-33
11. Choo P.W., Galil K., Donahue J.G., Walker A.M., Spiegelman D., and Platt R. Risk factors for postherpetic neuralgia. Arch. Intern. Med. 157 (1997) 1217-1224
12. Helgason S., Petursson G., Gudmundsson S., and Sigurdsson J.A. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 321 (2000) 794-796
13. Jung B.F., Johnson R.W., Griffin D.R.J., and Dworkin R.H. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62 (2004) 1545-1551
14. Arvin A., and Gershon A. Control of varicella: why is a two-dose schedule necessary?. Pediatr. Infect. Dis. J. 25 (2006) 475-476
15. Knuf M., Habermehl P., Zepp F., Mannhardt W., Kuttnig M., Muttonen P., et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr. Infect. Dis. J. 25 (2006) 12-18
16. Verstraeten T., Jumaan A.O., Mullooly J.P., Seward J.F., Izurieta H.S., DeStefano F., et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 112 (2003) e98-e103
17. Hambleton S., and Gershon A.A. Preventing varicella-zoster disease. Clin. Microbiol. Rev. 18 (2005) 70-80
18. Sharrar R.G., LaRussa P., Galea S.A., Steinberg S.P., Sweet A.R., Keatley R.M., et al. The postmarketing safety profile of varicella vaccine. Vaccine 19 (2000) 916-923
19. Vázquez M., LaRussa P.S., Gershon A.A., Niccolai L.M., Muehlenbein C.E., Steinberg S.P., et al. Effectiveness over time of varicella vaccine. JAMA 291 (2004) 851-855
20. Asano Y., Nakayama H., Yazaki T., Kato R., and Hirose S. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 59 (1977) 3-7
21. Watson B., Seward J., Yang A., Witte P., Lutz J., Chan C., et al. Postexposure effectiveness of varicella vaccine. Pediatrics 105 (2000) 84-88
22. Comité technique des vaccinations DGS. Guide des vaccinations Édition 2006 (2006), Éditions Inpes 284-288
23. Shields K.E., Galil K., Seward J., Sharrar R.G., Cordero J.F., and Slater E. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet. Gynecol. 98 (2001) 14-19
24. Gershon A.A. Prevention and treatment of VZV infections in patients with HIV. Herpes 8 (2001) 32-36
25. Levin M.J., Gershon A.A., Weinberg A., Blanchard S., Nowak B., Palumbo P., et al. Immunization of HIV-infected children with varicella vaccine. J. Pediatr. 139 (2001) 305-310
26. Levin M.J., Gershon A.A., Weinberg A., Song L.-Y., Fentin T., Nowak B., et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J. Infect. Dis. 194 (2006) 247-255
27. Gershon A.A., Takahashi M., and Seward J. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines, 4th Edition (2004), Saunders, Philadelphia 783-824
28. Tsolia M., Gershon A.A., Steinberg S.P., and Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J. Pediatr. 116 (1990) 184-189
29. Gershon A.A. Varicella vaccine: rare serious problems-but the benefits still outweigh the risks. J. Infect. Dis. 188 (2003) 945-947
30. Wise R.P., Salive M.E., Braun M.M., Mootrey G.T., Seward J.F., Rider L.G., et al. Postlicensure safety surveillance for varicella vaccine. JAMA 284 (2000) 1271-1279
31. Levin M.J., Dahl K.M., Weinberg A., Giller R., Patel A., and Krause P.R. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J. Infect. Dis. 188 (2003) 954-959
32. Jumaan A.O., Yu O., Jackson L.A., Bohlke K., Galil K., and Seward J.F. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis. 191 (2005) 2002-2007
33. Pinot de Moira A., and Nardone A. Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill. 10 (2005) 43-45
34. Jerant A.F., DeGaetano J.S., Epperly T.D., Hannapel A.C., Miller D.R., and Lloyd A.J. Varicella susceptibility and vaccination strategies in young adults. J. Am. Board Fam. Pract. 11 (1998) 296-306
35. Centers for Disease Control and Prevention. Estimated vaccination coverage with individual vaccines and selected vaccination series among children 19-35 months of age by state and immunization action plan area, US, National Immunization Survey. 2005; last accessed: Octobre 2006. Available from: http://www.cdc.gov/nip/coverage/NIS/05/toc-05.htm.
36. Seward J.F., Watson B.M., Peterson C.L., Mascola L., Pelosi J.W., Zhang J.X., et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 287 (2002) 606-611
37. Zhou F., Harpaz R., Jumaan A.O., Winston C.A., and Shefer A. Impact of varicella vaccination on health care utilization. JAMA 294 (2005) 797-802
38. Nguyen H.Q., Jumaan A.O., and Seward J.F. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N. Engl. J. Med. 352 (2005) 450-458
39. Galil K., Lee B., Strine T., Carraher C., Baughman A.L., Eaton M., et al. Outbreak of varicella at a day-care center despite vaccination. N. Engl. J. Med. 347 (2002) 1909-1915
40. Haddad M.B., Hill M.B., Pavia A.T., Green C.E., Jumaan A.O., De A.K., et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 115 (2005) 1488-1493
41. Brisson M., Edmunds W.J., and Gay N.J. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J. Med. Virol. 70 Suppl. 1 (2003) S31-S37
42. Yih W.K., Brooks D.R., Lett S.M., Jumaan A.O., Zhang Z., Clements K.M., et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 5 (2005) 68
43. Whitley R.J. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J. Infect. Dis. 191 (2005) 1999-2001
44. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352 (2005) 2271-2284